Autolus Therapeutics (AUTL) Current Assets (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Current Assets for 9 consecutive years, with $435.9 million the latest figure, recorded in Q4 2025.

• Quarterly Current Assets fell 34.05% year-over-year to $435.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $435.9 million (down 34.05% YoY) and the FY2025 annual result came in at $435.9 million, down 34.05% from the prior year.
• Current Assets retreated to $435.9 million in Q4 2025 per AUTL's latest filing, from $514.6 million in the prior quarter.
• Over the last five years, Current Assets for AUTL reached as high as $804.3 million in Q1 2024 and fell as low as $212.3 million in Q3 2022.
• A 5-year average of $438.2 million and a median of $374.6 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2023 — Current Assets slumped 35.34% — and 2024, when it jumped 140.07%.
• Year by year, Current Assets stood at $347.0 million in 2021, then grew by 22.72% to $425.8 million in 2022, then sank by 35.34% to $275.3 million in 2023, then soared by 140.07% to $660.9 million in 2024, then slumped by 34.05% to $435.9 million in 2025.
• According to Business Quant data, Current Assets over the past three periods registered $435.9 million, $514.6 million, and $574.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.